Haemonetics Corporation (HAE)
NYSE: HAE · Real-Time Price · USD
78.78
+1.38 (1.78%)
Jul 24, 2026, 4:00 PM EDT - Market closed
Haemonetics Balance Sheet
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 28, 2026 | Mar '25 Mar 29, 2025 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 |
Cash & Equivalents | 245.44 | 306.76 | 178.8 | 284.47 | 259.5 |
Cash & Short-Term Investments | 245.44 | 306.76 | 178.8 | 284.47 | 259.5 |
Cash Growth | -19.99% | 71.57% | -37.15% | 9.62% | 34.94% |
Accounts Receivable | 216.86 | 202.66 | 206.56 | 179.14 | 159.38 |
Inventory | 306.37 | 365.14 | 317.2 | 259.38 | 293.03 |
Other Current Assets | 66.21 | 60.41 | 66.34 | 46.74 | 44.13 |
Total Current Assets | 834.88 | 934.98 | 768.9 | 769.72 | 756.03 |
Net Property, Plant & Equipment | 305.76 | 284.05 | 311.36 | 310.89 | 258.48 |
Other Intangible Assets | 447.66 | 455.74 | 406.12 | 275.77 | 310.26 |
Goodwill | 656.37 | 604.27 | 565.08 | 466.23 | 467.29 |
Other Long-Term Assets | 151.26 | 171.91 | 144.13 | 112.22 | 67.67 |
Total Assets | 2,396 | 2,451 | 2,196 | 1,935 | 1,860 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 28, 2026 | Mar '25 Mar 29, 2025 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 |
Accounts Payable | 51.06 | 67 | 73.36 | 63.93 | 58.37 |
Accrued Expenses | 68.19 | 59.42 | 80.71 | 64.48 | 48.54 |
Short-Term Debt | 5.02 | 303.56 | 10.23 | 11.78 | 214.15 |
Other Current Liabilities | 158.34 | 148.13 | 136.09 | 111.63 | 121.21 |
Total Current Liabilities | 282.6 | 578.11 | 300.38 | 251.82 | 442.27 |
Long-Term Debt | 1,220 | 921.23 | 797.56 | 754.1 | 559.44 |
Other Long-Term Liabilities | 97.44 | 130.77 | 137.69 | 110.91 | 108.6 |
Total Long-Term Liabilities | 1,317 | 1,052 | 935.25 | 865.01 | 668.04 |
Total Liabilities | 1,600 | 1,630 | 1,236 | 1,117 | 1,110 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 28, 2026 | Mar '25 Mar 29, 2025 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 |
Common Stock | 0.45 | 0.48 | 0.51 | 0.5 | 0.51 |
Additional Paid-in Capital | 554.14 | 523.26 | 634.63 | 594.71 | 572.48 |
Accumulated Other Comprehensive Income | -37.61 | -55.08 | -35.63 | -30.38 | -25.95 |
Retained Earnings | 279.34 | 352.17 | 360.46 | 253.17 | 202.39 |
Shareholders' Equity | 796.32 | 820.84 | 959.96 | 818 | 749.42 |
Total Liabilities & Equity | 2,396 | 2,451 | 2,196 | 1,935 | 1,860 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 28, 2026 | Mar '25 Mar 29, 2025 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 |
Total Debt | 1,225 | 1,225 | 807.79 | 765.89 | 773.59 |
Net Cash (Debt) | -979.14 | -918.03 | -628.99 | -481.42 | -514.09 |
Net Cash Growth | - | - | - | - | - |
Net Cash Per Share | -20.68 | -18.10 | -12.24 | -9.36 | -10.01 |
Book Value | 796.32 | 820.84 | 959.96 | 818 | 749.42 |
Book Value Per Share | 16.82 | 16.18 | 18.68 | 15.91 | 14.59 |
Tangible Book Value | -307.7 | -239.18 | -11.24 | 76 | -28.12 |
Tangible Book Value Per Share | -6.50 | -4.71 | -0.22 | 1.48 | -0.55 |